科兴制药实控人方75天减持1831万股 套现8.53亿元

Core Viewpoint - Recently, Sinovac Biotech (688136.SH) disclosed the results of a shareholder inquiry transfer report and a notice regarding changes in the equity of shareholders holding more than 5% of shares, indicating significant share reductions by its major shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. [1] Summary by Relevant Sections Shareholder Equity Changes - Shenzhen Keyi Pharmaceutical reduced its holdings by a total of 18,314,717 shares, which represents 9.62% of the company's total equity [2][3] - The share reductions occurred through various methods, including a block trade and inquiry transfers, with specific dates and amounts detailed [2] Financial Impact - The average share price during the reduction period was 46.60 RMB, leading to a total cash-out amount of approximately 853,465,812.2 RMB [1] Ownership Structure Post-Reduction - After the reductions, Shenzhen Keyi Pharmaceutical holds 109,688,630 shares, accounting for 54.50% of the total equity, while its associated party, Deng Xueqin, holds 1,764,125 shares, or 0.88% [2][3] - The combined holdings of Shenzhen Keyi Pharmaceutical and Deng Xueqin amount to 111,452,755 shares, representing 55.38% of the total equity [3] Control and Governance - The transfer of shares will not result in a change of the controlling shareholder or the actual controller of the company, and it is not expected to significantly impact the company's governance structure or ongoing operations [3]